Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
-
Noosa News23 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General16 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News16 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General18 hours agoPerth man charged after investigation into organised crime and tobacco store attacks